Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), a leader in RNA interference (RNAi) therapeutics, stands at a pivotal juncture as it seeks to capitalize on the burgeoning market for ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

These are unquestionably serious issues, but Merck remains a top stock to buy and hold, at least for investors focused on the long game. Here's why. Merck's Keytruda generates over $20 billion in ...

Exicure announced the acquisition of GPCR Therapeutics USA Inc. (GPCR USA), a significant step that could reshape the company’s future. Under the terms of the agreement, Exicure acquired all the ...

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

As 2025 begins, the American Association for Cancer Research (AACR) recently published forecasts from experts showcasing ...

DelveInsight's NSCLC pipeline report depicts a robust space ... OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience - Novimmune SA, Immunitas Therapeutics, Hansoh BioMedical ...

Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Tenaya Therapeutics (TNYA ... promising progress in their clinical pipeline and anticipated milestones for ...

VYNE Therapeutics ... entry point, with endpoints focused on critical clinical outcomes. With a strong financial position extending into 2026, VYNE is well-positioned to advance its pipeline ...

Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial Over the past 15 years, the landscape ...